La cadena de opciones muestra datos clave de las opciones de acciones de GoodRx Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para GoodRx Holdings..

GoodRx Holdings (NASDAQ:GDRX) Bolsa, Cadena de Opciones

GoodRx Holdings

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings Inc

Congress gathered on Monday to certify <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">President-elect Donald Trump's election</a> victory under the tightest national security levels possible in a stark reminder of four years ago when the U.S. Capitol <a href="https://www.benzinga.com/government/21/01/19049660/washington-dc-descends-into-anarchy-as-trump-supporters-storm-us-capitol-delay-electoral-college-vot">descended into chaos and violence</a> on Jan. 6, 2021, when lawmakers gathered to certify then-President-elect Joe Biden's win.
<h2 class="wp-block-heading">Things Are Different This Jan. 6: &#8216;Democracy Prevails&#8217; </h2>
When Vice President Kamala Harris walked into the Senate chamber on Monday to undertake the traditional role of certifying the national election, she issued a simple declaration when asked about the procedure by NBC News. "Democracy prevails," she said. 
Harris oversaw the process as four senators confirmed each state&#8217;s votes, which she lost to Trump, resulting in his return to the White House. Once the total vote reached a threshold, Harris certified Trump&#8217;s election victory.
&#8220;I do believe very strongly that America&#8217;s democracy is only as strong as our willingness to fight for it &#8230; Otherwise, it is very fragile, and it will not be able to withstand moments of crisis. And today, America&#8217;s democracy stood,&#8221; Harris said in comments after the count, <a href="https://abcnews.go.com/Politics/congress-meets-certify-trumps-2024-election-victory/story?id=117380065">reported</a> ABC News
NBC <a href="https://www.nbcnews.com/politics/kamala-harris/kamala-harris-approaching-certifying-election-loss-trump-rcna186298">reported</a> that Harris broke into a smile upon receiving a standing ovation from the Democratic party when her own vote total for the November election was read. The totals were 75,000,783 votes for Harris to Trump's 77,285,106.
<h2 class="wp-block-heading">Former VP Mike Pence Seemed Calmer This January 6</h2>
Trump&#8217;s former Vice President, Mike Pence, who faced <a href="https://www.cnn.com/videos/politics/2021/01/15/mike-pence-close-call-capitol-riot-foreman-vpx.cnn">threats </a>from rioters during the Jan. 6 attack on the Capitol—an event some allege <a href="https://www.benzinga.com/news/23/10/35528275/experts-testify-on-jan-6-in-trumps-14th-amendment-colorado-case-ex-president-expressed-messages-that">was incited by Trump</a>—sounded much calmer this year.
"The peaceful transfer of power is the hallmark of our democracy and today, members of both parties in the House and Senate along with the vice president certified the election of our new president and vice president without controversy or objection," he <a href="https://x.com/Mike_Pence/status/1876340275037266113">said</a> in on X.  
In the days and weeks after the Jan. 6 Capitol riot, seven people, including three law enforcement officers, lost their lives, according to a <a href="https://www.hsgac.senate.gov/imo/media/doc/HSGAC&amp;RulesFullReport_ExaminingU.S.CapitolAttack.pdf" target="_blank" rel="noreferrer noopener">bipartisan</a> Senate report. 
This Jan 6, 2025, the confirmation process went off without incident and was over in about 30 minutes.
Now read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42827796/maga-meme-coin-surges-20-boosting-donald-trumps-crypto-portfolio-11-9m">MAGA Meme Coin Surges 20%, Boosting Donald Trump&#8217;s Crypto Portfolio $11.9M</a></li>
</ul>
Photo: miss.cabul/Shutterstock.com

Government

News

Politics

Trump Confirmed President By VP Harris As Pence Hails 'Peaceful Transfer' This Jan. 6

Legendary investor Warren Buffett had a 2024 to remember with Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) reaching the $1 trillion market capitalization milestone for <a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig">the first time.</a>
During the year, Buffett&#8217;s Berkshire Hathaway also outperformed the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>). 
Overall, Berkshire Hathaway stock was up 27.1% in 2024 versus a 24.1% gain for SPDR S&amp;P 500 ETF Trust, according to data from <a href="https://www.macrotrends.net/stocks/charts/BRK.B/berkshire-hathaway/stock-price-history">Macrotrends</a>. That&#8217;s despite Berkshire Hathaway offloading top-performing Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock<a href="https://www.benzinga.com/markets/equities/24/12/42666459/warren-buffett-once-called-berkshire-the-opposite-of-those-who-hurry-to-sell-now-hes-offloading-apple-and-snapping-up-occidental-petroleum-amid-a-20-drop"> during the year.</a>
Here's a look at the gains of Berkshire Hathaway B shares vs. the SPY over the last 20 <a href="https://www.macrotrends.net/stocks/charts/SPY/spdr-s-p-500-etf/stock-price-history">years</a>:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>YEAR</td>
<td>BRK-B</td>
<td>SPY</td>
<td>WINNER</td>
</tr>
<tr>
<td>2024</td>
<td>+27.1%</td>
<td>+24.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2023</td>
<td>+15.5%</td>
<td>+26.7%</td>
<td>SPY</td>
</tr>
<tr>
<td>2022</td>
<td>+3.3%</td>
<td>-17.5%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2021</td>
<td>+29.0%</td>
<td>+28.7%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2020</td>
<td>+2.4%</td>
<td>+18.4%</td>
<td>SPY</td>
</tr>
<tr>
<td>2019</td>
<td>+10.9%</td>
<td>+31.2%</td>
<td>SPY</td>
</tr>
<tr>
<td>2018</td>
<td>+3.0%</td>
<td>-4.6%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2017</td>
<td>+21.6%</td>
<td>+21.7%</td>
<td>SPY</td>
</tr>
<tr>
<td>2016</td>
<td>+23.4%</td>
<td>+12.0%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2015</td>
<td>-12.1%</td>
<td>+1.3%</td>
<td>SPY</td>
</tr>
<tr>
<td>2014</td>
<td>+26.6%</td>
<td>+13.5%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2013</td>
<td>+32.2%</td>
<td>+32.3%</td>
<td>SPY</td>
</tr>
<tr>
<td>2012</td>
<td>+17.6%</td>
<td>+16.0%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2011</td>
<td>-4.8%</td>
<td>+1.9%</td>
<td>SPY</td>
</tr>
<tr>
<td>2010</td>
<td>+21.9%</td>
<td>+15.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2009</td>
<td>+2.2%</td>
<td>+26.4%</td>
<td>SPY</td>
</tr>
<tr>
<td>2008</td>
<td>-32.1%</td>
<td>-36.8%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2007</td>
<td>+29.2%</td>
<td>+5.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2006</td>
<td>+24.9%</td>
<td>+15.9%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2005</td>
<td>-.02%</td>
<td>+4.8%</td>
<td>SPY</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">The chart shows which stock performed better in the right-hand column.</figcaption></figure>
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
<h3 class="wp-block-heading">Key Points: Buffett Vs. SPY</h3>
Berkshire Hathaway beat the S&amp;P 500 in 2024, but significantly underperformed in 2023.
The last down year for the S&amp;P 500 came in 2022 with the SPY down 17.5% for the year. For Berkshire Hathaway, the last down year was in 2015, with a 12.1% decline.
Over the last 20 years, the best return for the SPY was +32.3% in 2013, just outperforming Berkshire Hathaway at +32.2% in the same year.
A look at the worst year also sees SPY win with a 36.8% decline in 2008 compared to a 32.1% decline for Berkshire Hathaway in the same year.
Overall, in the last 20 years, Buffett has won the head-to-head battle 11 times with SPY winning nine times. 
Taking the average return of the last 20 years, Berkshire Hathaway leads at 12.1% to 11.5%.
More importantly, the 20-year return is +669% for Berkshire Hathaway compared to a 20-year return of +621.2% for SPY, adjusted for dividends.
When it comes to investing in the SPY vs. Berkshire Hathaway, the Oracle of Omaha leads the battle across many metrics over the last 20 years, including overall returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42734838/warren-buffetts-chilling-warning-to-employees-lose-a-shred-of-reputation-for-the-firm-and-i-will-be-ruthless">Warren Buffett&#8217;s Chilling Warning To Employees: &#8216;Lose A Shred Of Reputation For The Firm And I Will Be Ruthless&#8217;</a></li>
</ul>
Image: Shutterstock

Broad U.S. Equity ETFs

Education

Management

Trading Ideas

ETFs

AAPL

Warren Buffett Beats S&P 500 In 2024, How Oracle Of Omaha's Returns Compare Over Past 20 Years

Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares are trading higher in Monday&#8217;s after-hours session after the company announced a CEO transition and <a href="https://www.benzinga.com/pressreleases/25/01/b42830392/ulta-beauty-announces-ceo-transition">updated its near-term outlook</a>.
What Happened: After the market close on Monday, Ulta announced that Dave Kimbell will retire as CEO and step down from the company&#8217;s board, effective immediately.
President and COO Kecia Steelman will succeed Kimbell as president and CEO, effective as of Monday. Steelman will also join the company&#8217;s board. 
&#8220;Kecia is a world-class business executive with deep beauty and retail expertise, an unwavering commitment to effective execution, and a profound passion for our guests and associates. She has been instrumental in developing our recently refreshed strategic framework, and we are confident that she is the right person to lead Ulta Beauty forward,&#8221; said Lorna Nagler, chair of Ulta Beauty&#8217;s board.
See Also: <a href="https://www.benzinga.com/25/01/42825782/bath-body-works-loyalty-program-shines-in-holiday-sales-says-analyst">Bath &amp; Body Works Undervalued: Goldman Sachs Sees Upside Amid Strong Candle Day Performance</a>
In addition to the CEO transition, Ulta updated its fourth-quarter guidance to reflect stronger-than-expected performance during the holiday season. 
The company now expects comparable sales to &#8220;increase modestly.&#8221; Ulta also said it expects operating margin to be above the high-end of the company&#8217;s previous expected range of&nbsp;11.6%&nbsp;to&nbsp;12.4% of sales. 
Ulta is scheduled to report fourth-quarter financial results on March 13. Analysts currently expect the company to report earnings of $6.73 per share and revenue of $3.4 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;I am confident the strategic priorities we shared last fall will enable us to capture greater market share in beauty and wellness and deliver long-term profitable growth, and I am excited to lead our outstanding teams as we unlock even greater advantages of our operating model, drive best-in-class execution, and position Ulta Beauty for our next chapter of growth as the beauty destination for a lifetime,&#8221; Steelman said. 
ULTA Price Action: <a href="http://benzinga.com/quote/ulta">Ulta Beauty shares</a> were up 2.48% after hours, trading at $442 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

Movers

General

ULTA

Ulta Beauty Stock Is Rising After Hours: Here's Why

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 2.69% on an annualized basis producing an average annual return of 14.37%. Currently, Graphic Packaging Holding has a market capitalization of $7.94 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 15 years ago, it would be worth $7,385.47 today based on a price of $26.44 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=Stoke+Therapeutics%2C+Inc.&amp;index=1&amp;md5=454f1331ad469e0bb2ff820d8c29374c">Stoke Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors &amp; News section of Stoke's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;index=2&amp;md5=0cb1b30b6a3643c6103e41277dc36c53">https://investor.stoketherapeutics.com/</a>. Research analysts who plan to join the call and participate in the Q&amp;A session may register <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIfb7a43c079834c3cb6a0813f54c1059e&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=7af8fd1c74d79d04b91cc2894bac615b">here</a> to receive the dial-in details and a unique PIN. For all others, the listen-only webcast can be accessed by clicking <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fmj8c7ajk&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=8eeec19293664ff83d3ffc6172d6dc34">here</a>. A replay of the webcast will be archived and available for at least 90 days following the event.

Biotech

Events

STOK

Stoke Therapeutics To Host Webcast To Discuss Successful Global Regulatory Alignment For A Phase 3 Study Of Zorevunersen As Potentially The First Disease Modifying Medicine For Dravet Syndrome On January 7, 2025 At 8:00am Eastern Time

Equus Appoints Fraser Atkinson As Chairman

– Mollie Leoni, M.D. promoted to Chief Medical Officer –
– Francis Burrows, Ph.D. promoted to Chief Scientific Officer –
– Stephen Dale, M.D., steps down as CMO and Head of R&amp;D to prioritize personal health –
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, M.D., has been promoted to Chief Medical Officer after serving as Executive Vice President of Clinical Development and clinical lead for the Company's ziftomenib program since 2020. In addition, Francis Burrows, Ph.D., has been promoted to Chief Scientific Officer after leading the Company's translational research efforts for the past nine years. Stephen Dale, M.D., has stepped down as Chief Medical Officer, effective as of January 2, 2025, to focus on recovery from personal health challenges.

KURA

Kura Oncology Announces Senior Executive Promotions; Mollie Leoni, Promoted To Chief Medical Officer; Stephen Dale Steps Down As CMO And Head Of R&D To Prioritize Personal Health

ENVX

Enovix Completes Site Acceptance Testing Of Fab2

Sheridan C. Swords, previously executive vice president, commercial liquids and natural gas gathering and processing, is assuming the newly created position of executive vice president and chief commercial officer.&nbsp;
 &nbsp;

ONEOK Names Randy N. Lentz To Newly Created Position Of Executive Vice President And COO;

<ul>
<li>Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo</li>
<li>Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases</li>
<li>Company reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026</li>
</ul>
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=027Hc0iV9b3bn31fIYu-D_K2UCwWK-kHIEeCWObZ_SYoKcLmk_FTbqmyuakhho9D_puGTMCU4fcrMVn_xRE377LIYsBdVqYhVAkwMl-lP1bnLAothOYz1lzNzcCUGCtUZ-ql2y8lzaklBO-Z3eX5LvyqZqdKorEbxHNadzB1MVHlTX8vWFpNiycqI5P_fTVwJyGqJwJziyyNlnFNSvbQ7DNZjz3EI11B6LKd-_LuIsOuQVtCVBoqV7eVloXCn-mLYI1FrHvSpQslCrcpjngxjg==">Generation Bio Co.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells.

GBIO

Generation Bio To Apply ctLNP Delivery Technology To Develop siRNA Therapeutics For T Cell-Driven Autoimmune Diseases

During the interim period until the transaction closes, Ansys will continue to offer Ansys PowerArtist as part of its product line, and is committed to providing the same high-quality service its customers have come to expect.

Asset Sales

ANSS

Ansys Says Sale Of PowerArtist Is Not Material To Its Financials; Terms Of Agreement Were Not Disclosed

Ansys and Synopsys determined that the sale of PowerArtist was necessary to obtain regulatory approval for Synopsys' proposed acquisition of Ansys.

KEYS

SNPS

Ansys Enters Definitive Agreement For Sale Of Its PowerArtist Business To Keysight Technologies

<ul>
<li>Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks</li>
<li>Overall, DNL343 was found to be safe and well tolerated</li>
<li>Additional analyses, including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025 &nbsp;</li>
</ul>

DNLI

Denali Therapeutics Announces Topline Results For Regimen G Evaluating eIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial; Study Did Not Meet Primary Endpoint

NNN REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>), a real estate investment trust, today announced that Kevin B. Habicht, Executive Vice President, Chief Financial Officer, Assistant Secretary, Treasurer and the Company's principal financial officer, will retire and step down as a member of the Board of Directors effective March 31, 2025.&nbsp; Vincent H. Chao will join NNN as Executive Vice President on January 9, 2025, and assume the positions of Chief Financial Officer, Assistant Secretary and Treasurer and serve as the Company's principal financial officer effective April 1, 2025.
Mr. Habicht has served as Executive Vice President and Chief Financial Officer of the Company since December 1993, and as Treasurer of the Company since January 1998 and as a director of the Company since June 2000. Mr. Habicht served as Secretary of the Company from January 1998 to May 2003.

NNN REIT Announces Kevin B. Habicht, Executive Vice President, CFO, Assistant Secretary, Treasurer And The Co's Principal Financial Officer, Will Retire, Effective March 31, 2025. Vincent H. Chao Will Join As Executive Vice President On January 9, 2025, And Assume The Positions Of CFO, Assistant Secretary And Treasurer And Serve As The Co's Principal Financial Officer Effective April 1, 2025

Jack A. Hockema, Executive Chair of the Board of Directors and Chair of the Executive Committee of the Board, notified the Board of his decision to retire as a director of the Company, effective January 1, 2025.&nbsp;
&nbsp;

KALU

Kaiser Aluminum Names Keith A. Harvey,  Company's President, CEO And A Director, As Chairman Of The Board

Contracts

MPTI

MtronPTI Receives Over $10M Production Contract For A US Defense Program

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 12.62% on an annualized basis producing an average annual return of 25.44%. Currently, Krystal Biotech has a market capitalization of $4.45 billion. 
Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $3,017.82 today based on a price of $155.81 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) shares traded higher on Monday. Here&#8217;s what <a href="https://www.benzinga.com/general/travel/25/01/42809678/delta-southwest-american-and-others-airlines-halt-over-1300-flights-on-monday-after-severe-winter-storm">you need to know</a>.
What To Know: <a href="https://www.benzinga.com/general/travel/24/12/42705878/airline-stocks-outperform-tech-in-2024-holiday-travel-expected-to-see-records-this-year">Airlines</a> and other travel-related stocks moved higher on Monday after Transportation Security Administration (TSA) traveler screening data showed record travel figures for the end of 2024.
Near the end of last week, TSA <a href="https://x.com/TSA/status/1875202022737412371">posted</a> on X that it screened almost 39 million individuals from Dec. 19 through Jan. 2, marking its &#8220;busiest end of year travel period ever.&#8221; For all of 2024, TSA said officers screened a record 904 million people at airport checkpoints across the nation.
The government agency <a href="https://www.tsa.gov/travel/passenger-volumes/2024">reported</a> that 2,172,907 travelers were screened on New Year&#8217;s Eve, 2,039,342 were screened on Christmas and 1,551,896 were screened on Thanksgiving.
The increase in TSA screenings indicates strong demand for air travel during the holiday season, which may boost ticket sales and revenue for airlines. Additionally, the high number of passengers highlights the resilience of the travel industry, suggesting continued post-pandemic growth.
Investors won&#8217;t have to wait long to get holiday travel data from the airlines. Notably, Delta is expected to release 2024 fourth-quarter and fiscal-year earnings at the end of the week. Analysts expect quarterly earnings per share of $1.76 and revenue of $14.19 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. Several other airlines are scheduled to report earnings in the coming weeks. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42828238/gemini-resolves-cftc-lawsuit-with-5m-settlement-over-bitcoin-futures-misstatements">Gemini Resolves CFTC Lawsuit With $5M Settlement Over Bitcoin Futures Misstatements</a>
DAL, AAL, LUV Price Action: Delta shares shares closed Monday up 1.75% at $60.03, American shares closed the day up 3.24% at $17.52 and Southwest shares closed up 0.62% at $33.82, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image via Shutterstock

Travel

What's Going On With Delta, American And Southwest Airlines Shares Monday?

APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) today announced key updates to its executive leadership and corporate officers.
Clay Bretches, executive vice president, Operations, has announced plans to retire July 1, 2025. As part of its commitment to maintaining excellence in operations, the company has launched an internal and external search for a new leader to drive continued innovation and operational efficiency. Bretches will remain with the organization and help ensure a smooth transition to a new leader, anticipated in the first half of 2025.

APA Corporation Announces Clay Bretches, Executive Vice President, Operations, Has Announced Plans To Retire July 1, 2025

New financing arrangement reduces Company's cost of capital by approximately 40%
Further enhances financial flexibility, cash generation and ability to support growth strategy
CHICAGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) ("FreightCar America" or the "Company"), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced it has completed a new term loan facility. The proceeds from the term loan will be used to redeem all outstanding shares of Series C Preferred Stock, as well as settle all related accrued dividends.
Highlights:
<ul>
<li>The Company closed a $115 million 4-year term loan agreement on December 31st, 2024 (the "Term Loan").</li>
<li>Proceeds from the Term Loan were used to redeem all 85,412 shares of Series C Preferred Stock that were outstanding and all accrued dividends as of December 31st, 2024.</li>
<li>The Term Loan is priced at SOFR + 600, which will reduce the Company's existing cost of capital by approximately 40%, resulting in savings of approximately $9.2 million in the first year, or approximately $0.26 per share on a fully diluted basis.</li>
</ul>

Financing

RAIL

FreightCar America Announces Agreement To Redeem All Outstanding Preferred Shares With New Term Loan; New Financing Arrangement Reduces Company's Cost Of Capital By ~40%

GoodRx Holdings ( ($GDRX) ) has shared an update. GoodRx Holdings has appointed Wendy Barnes as its new Chief Executive Officer and President, effe...

GoodRx Holdings Appoints Wendy Barnes as CEO

In a report released yesterday, Allen Lutz from Bank of America Securities maintained a Sell rating on GoodRx Holdings (GDRX – Research Report), wi...

Sell Rating Maintained for GoodRx Holdings Amid Volatility and Strategic Challenges

Wells Fargo analyst Stan Berenshteyn has maintained their bullish stance on GDRX stock, giving a Buy rating yesterday. Stan Berenshteyn has given h...

Strategic Leadership Shift at GoodRx: Analyst Recommends 'Buy' as New CEO Appointed

Analyst Daniel Grosslight of Citi maintained a Buy rating on GoodRx Holdings (GDRX – Research Report), retaining the price target of $7.00. Daniel ...

Positive Outlook for GoodRx Holdings Under New Leadership: Buy Rating and 52.5% Potential Return

Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on GoodRx Holdings (GDRX – Research Report) today and set a price target of $6.00....

Morgan Stanley Sticks to Their Hold Rating for GoodRx Holdings (GDRX)

Morgan Stanley lowered the firm's price target on GoodRx (GDRX) to $6 from $7 and keeps an Equal Weight rating on the shares. Diversified Managed C...

GoodRx price target lowered to $6 from $7 at Morgan Stanley

The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are strategically positioned to thrive in the sector, making them attractive investment opportunities. Read on… The digital health industry is booming, driven by technological advancements, rising health awareness, and a growing aging population. This presents a golden opportunity to tap into Hims &amp; Hers Health, Inc. (<a href="https://stocknews.com/stock/HIMS/">HIMS</a>), GoodRx Holdings, Inc. (<a href="https://stocknews.com/stock/GDRX/">GDRX</a>), and Talkspace, Inc. (<a href="https://stocknews.com/stock/TALK/">TALK</a>), which are well-positioned to ride the exciting growth wave of digital health.
As the global geriatric population continues to grow, the need for constant health management has never been more critical. Coupled with an increasing focus on health and wellness, people are increasingly seeking proactive and personalized healthcare. This shift is fueling the adoption of digital health technologies at an unprecedented rate.
Technological advancements are at the heart of this surge. <a href="https://www.techtarget.com/searchhealthit/definition/digital-health-digital-healthcare">Wearable devices</a>, mobile health applications, and telemedicine platforms are transforming healthcare. Artificial intelligence and machine learning, in particular, are revolutionizing healthcare applications, from image analysis and patient monitoring to medical device automation, enhancing clinical workflows and efficiency.
The surge in mobile and smartphone subscriptions is another key factor driving this growth. With <a href="https://www.demandsage.com/smartphone-usage-statistics/">approximately 7.21 billion</a> smartphone users globally, representing around 90% of the world's population, mobile devices are becoming essential tools for accessing digital health solutions. This growing mobile connectivity is crucial for the future of digital health.
Looking forward, as per a report by Fortune Business Insights, the global digital health market is expected to soar from $376.68 billion in 2024 to $1.50 trillion by 2032, exhibiting <a href="https://www.fortunebusinessinsights.com/industry-reports/digital-health-market-100227">a CAGR of 18.9%</a>. The rapid expansion indicates the vast potential and lucrative opportunities within the digital health sector.
So, let us dive deep into the fundamentals of three digital health stocks, starting with #3.
Stock #3: Hims &amp; Hers Health, Inc. (<a href="https://stocknews.com/stock/HIMS/">HIMS</a>)
HIMS connects consumers with licensed healthcare professionals through its telehealth platform. Customers can easily purchase curated prescription and non-prescription health products and services directly through HIMS' websites or mobile apps, ensuring convenience and personalized care.
On November 21, HIMS announced that its customers could now supplement their treatment plans with daily <a href="https://investors.hims.com/news/news-details/2024/Hims--Hers-Expands-Nutrition-Support-to-Fuel-Customers-Weight-Loss-Journeys/default.aspx">meal replacement bars and shakes</a> to support their comprehensive weight loss journeys. These products are designed to enhance HIMS' doctor-approved, individualized weight management plans.
By providing a more holistic approach to weight loss, HIMS can strengthen its position as a comprehensive health solution provider, attracting a wider range of customers.
On September 18, HIMS announced an initiative to offer access to <a href="https://investors.hims.com/news/news-details/2024/Hims--Hers-to-Offer-Access-to-Compounded-GLP-1-Injections-for-as-Low-as-99Month-to-U.S.-Military-Veterans-Teachers-Nurses-and-First-Responders/default.aspx">commonly compounded GLP-1 prescriptions</a> for as low as $99 a month. The offer is available to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. This move will increase HIMS' customer base by tapping into vital and underserved groups.
For the fiscal third quarter that ended September 30, 2024, HIMS' revenue increased 77.1% year-over-year to $401.56 million. Its gross profit grew 69.7% from the year-ago value to $317.89 million. Moreover, the company's <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> rose 311.1% year-over-year to $51.10 million.
Additionally, total comprehensive income and net income per share attributable to common stockholders came in at $75.99 million and $0.32, compared to a net loss and loss per share of $7.44 million and $0.04 in the previous year's quarter, respectively.
Analysts expect HIMS' revenue and EPS for the fiscal fourth quarter ending December 2024 to increase 90.4% and 961.8% year-over-year to $469.48 million and $0.11, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
Shares of HIMS have surged 62.8% over the past six months and 281.6% over the past year, closing the last trading session at $33.92.
HIMS' <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> mirror its fundamentals. HIMS has an A grade for Quality and Growth. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, HIMS is ranked #33 out of 63 stocks. In addition to the POWR Rating highlighted above, you can check HIMS' ratings for Stability, Sentiment, Momentum, and Value <a href="https://stocknews.com/stock/HIMS/">here</a>.
Stock #2: GoodRx Holdings, Inc. (<a href="https://stocknews.com/stock/GDRX/">GDRX</a>)
GDRX provides a consumer-focused digital healthcare platform. The company offers a price comparison platform that provides consumers with relevant prescription pricing, and other healthcare products and services, as well as telehealth services through the GoodRx Care platform.
On October 31, GDRX <a href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-unveils-new-e-commerce-platform-launches-opillr">unveiled its new e-commerce platform</a> with Opill&#xAE; as its launch partner. This move could significantly enhance GDRX's competitive edge in the rapidly growing digital health market. By offering a streamlined, user-friendly shopping experience, GDRX strengthens its brand presence and attracts a broader customer base.
Additionally, on October 16, GDRX <a href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-partnering-retail-pharmacies-deliver-pay-over-time-option">announced a partnership</a> with retail pharmacies, including Hy-Vee, a grocery retailer with over 275 retail pharmacies. The collaboration introduces Affirm's "Pay Over Time" option for select medications.
By offering flexible payment plans, GDRX would be able to cater to a wider range of consumers, driving customer loyalty and increasing medication access. Additionally, the expansion into the retail pharmacy sector enables GDRX to tap into a larger market, broadening its reach and solidifying its leadership position in the healthcare space.
For the fiscal 2024 third quarter that ended September 30, GDRX's revenue increased 8.5% year-over-year to $195.25 million. Its adjusted operating income grew 17.6% from the year-ago value to $49.39 million.
Moreover, the company's adjusted net income and adjusted EPS rose 25% and 33.3% from the prior year's quarter to $31.94 million and $0.08, respectively.
Street expects GDRX's revenue and EPS for the fiscal year ending December 2025 to increase 4.1% and 120.5% year-over-year to $825.66 million and $0.16, respectively. In addition, the company topped the consensus revenue estimates in three of the four trailing quarters.
GDRX's shares surged 4.3% over the past five days to close the last trading session at $5.07.
GDRX's solid prospects are projected in its POWR Ratings. The stock has an overall rating of B, translating to a Buy in our proprietary rating system.
GDRX has an A grade for Growth and a B for Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, it is ranked #36 out of 156.
<a href="https://stocknews.com/stock/GDRX/">Click here</a> to access GDRX's ratings for Quality, Momentum, Sentiment, and Stability.
Stock #1: Talkspace, Inc. (<a href="https://stocknews.com/stock/TALK/">TALK</a>)
TALK operates a behavioral healthcare company that offers psychotherapy and psychiatry services through its platform to individuals, enterprises, health plans, and employee assistance programs. The company also offers text, audio, and video-based psychotherapy from licensed therapists.
On October 23, TALK <a href="https://investors.talkspace.com/news-releases/news-release-details/talkspace-teams-wisdo-health-tackle-loneliness-amongst-older">announced its strategic partnership</a> with Wisdo Health, an AI-powered platform addressing loneliness and improving mental health for the 65+ community. The collaboration expands TALK's services, enhancing access to mental health resources while reducing healthcare costs.
It could boost member engagement, address the growing senior mental health crisis, and position TALK as a leader in senior health, driving both growth and market expansion.
On September 17, TALK partnered with Amazon Health Services to enhance the <a href="https://investors.talkspace.com/news-releases/news-release-details/talkspace-partners-amazon-health-services-help-millions-discover">visibility of its mental health care services</a> on Amazon.com. The partnership allows millions of U.S. shoppers to easily discover TALK's behavioral health benefits, granting access to over 5,000 licensed therapists and increasing awareness and accessibility for those in need.
By tapping into the company's massive customer base, TALK can ensure more people are aware of its offerings, driving both growth and market penetration.
For the fiscal third quarter that ended September 30, 2024, TALK's total revenue increased 22.6% year-over-year to $47.40 million. Its gross profit grew 14.7% from the year-ago value to $21.62 million. Plus, the company's adjusted EBITDA came in at $2.35 million, compared to a loss of $2.80 million in the previous year's quarter.
Additionally, TALK reported a net income of $1.87 million and net income per share of $0.01, reversing the previous year's quarter's net loss of $4.41 million and loss per share of $0.03.
The consensus revenue and EPS estimates of $232.88 million and $0.06 for the fiscal year ending December 2025 exhibit a year-over-year rise of 23.3% and 833.3%, respectively. Furthermore, the company surpassed the consensus revenue estimates in three of four trailing quarters.
Shares of TALK have surged 39.9% over the past six months and 59.7% over the past year to close the last trading session at $3.61.
TALK's prospects are reflected in its POWR Ratings. The stock has a B grade for Sentiment and Quality.
Within the Medical - Services industry, TALK is ranked #30 out of 63 stocks. <a href="https://stocknews.com/stock/TALK/">Click here</a> to access its Momentum, Value, Growth, and Stability ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
HIMS shares rose $0.16 (+0.47%) in premarket trading Thursday. Year-to-date, HIMS has gained 281.12%, versus a 29.05% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/hims-gdrx-talk-3-digital-health-companies-enhancing-patient-engagement/>3 Digital Health Companies Enhancing Patient Engagement</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Digital Health Companies Enhancing Patient Engagement

GoodRx Holdings (GDRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 16. Analyst Michael Che...

GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects

Raymond James is adding UnitedHealth (UNH) as a current favorite following the stock's significant underperformance versus the S&P 500. The firm is...

Raymond James adds UnitedHealth to Analyst Current Favorites list, cuts GoodRx

Raymond James adds UnitedHealth, drops GoodRx from favorites list

GDRX

HIMS

TALK

Press Releases

GoodRx to Participate in Upcoming Investor Conferences

GoodRx Reports Third Quarter 2024 Results

Legal

GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

GoodRx Holdings

GoodRx Holdings (GDRX) Opciones

GoodRx Holdings (NASDAQ:GDRX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL